The stock of Heron Therapeutics Inc (HRTX) has seen a 1.05% increase in the past week, with a -1.54% drop in the past month, and a -37.05% decrease in the past quarter. The volatility ratio for the week is 7.47%, and the volatility levels for the past 30 days are at 6.01% for HRTX. The simple moving average for the last 20 days is 1.88% for HRTX stock, with a simple moving average of -25.89% for the last 200 days.
Is It Worth Investing in Heron Therapeutics Inc (NASDAQ: HRTX) Right Now?
The 36-month beta value for HRTX is at 1.80. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HRTX is 144.09M, and currently, shorts hold a 24.93% of that float. The average trading volume for HRTX on September 24, 2024 was 2.39M shares.
HRTX) stock’s latest price update
Heron Therapeutics Inc (NASDAQ: HRTX)’s stock price has decreased by -3.03 compared to its previous closing price of 1.98. However, the company has seen a 1.05% increase in its stock price over the last five trading sessions. prnewswire.com reported 2024-09-03 that SAN DIEGO, Sept. 3, 2024 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer.
Analysts’ Opinion of HRTX
Many brokerage firms have already submitted their reports for HRTX stocks, with Rodman & Renshaw repeating the rating for HRTX by listing it as a “Buy.” The predicted price for HRTX in the upcoming period, according to Rodman & Renshaw is $7 based on the research report published on June 13, 2024 of the current year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see HRTX reach a price target of $6. The rating they have provided for HRTX stocks is “Overweight” according to the report published on April 23rd, 2024.
Needham gave a rating of “Buy” to HRTX, setting the target price at $5 in the report published on March 13th of the current year.
HRTX Trading at -16.93% from the 50-Day Moving Average
After a stumble in the market that brought HRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.15% of loss for the given period.
Volatility was left at 6.01%, however, over the last 30 days, the volatility rate increased by 7.47%, as shares sank -2.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.87% lower at present.
During the last 5 trading sessions, HRTX rose by +1.26%, which changed the moving average for the period of 200-days by +33.61% in comparison to the 20-day moving average, which settled at $1.8817. In addition, Heron Therapeutics Inc saw 12.94% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HRTX starting from Forbes William P, who purchase 25,000 shares at the price of $1.09 back on Nov 17 ’23. After this action, Forbes William P now owns 79,000 shares of Heron Therapeutics Inc, valued at $27,250 using the latest closing price.
Forbes William P, the EVP, Chief Development Officer of Heron Therapeutics Inc, purchase 50,000 shares at $0.94 during a trade that took place back on Nov 16 ’23, which means that Forbes William P is holding 54,000 shares at $46,995 based on the most recent closing price.
Stock Fundamentals for HRTX
Current profitability levels for the company are sitting at:
- -0.34 for the present operating margin
- 0.65 for the gross margin
The net margin for Heron Therapeutics Inc stands at -0.35. The total capital return value is set at -0.34.
Based on Heron Therapeutics Inc (HRTX), the company’s capital structure generated 1.27 points at debt to capital in total, while cash flow to debt ratio is standing at -0.12. The debt to equity ratio resting at -4.68. The interest coverage ratio of the stock is -16.99.
Currently, EBITDA for the company is -107.72 million with net debt to EBITDA at -3.68. When we switch over and look at the enterprise to sales, we see a ratio of 3.34. The receivables turnover for the company is 1.85for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.38.
Conclusion
In conclusion, Heron Therapeutics Inc (HRTX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
